Intragastric acidity during administration of generic omeprazole or esomeprazole - A randomised, two-way crossover study including CYP2C19 genotyping

Alimentary Pharmacology and Therapeutics

Volumn 33, Issue 4, 2011, Pages 471-476

  Miehlke, S ^e   Lobe S ^a   Madisch, A ^b   Kuhlisch, E ^c   Laass, M ^a   Grossmann D ^a   Knoth, H ^a   Morgner, A ^a   Labenz, J ^d  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Siloah Hospital   (Germany)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d Diakonie Klinikum Jung Stilling   (Germany)

^e UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOCHROME P450 2C19; ESOMEPRAZOLE; NEXIUM MUPS; OMEP; OMEPRAZOLE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOATING; CROSSOVER PROCEDURE; DIARRHEA; DRUG INDUCED HEADACHE; DRUG METABOLISM; FEMALE; FLATULENCE; GENOTYPE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE BLIND PROCEDURE; STANDING; STOMACH PH; SUPINE POSITION;

ADOLESCENT; ADULT; ANTI-ULCER AGENTS; ARYL HYDROCARBON HYDROXYLASES; CROSS-OVER STUDIES; DRUGS, GENERIC; ENZYME INHIBITORS; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GASTRIC ACID; GASTRIC ACIDITY DETERMINATION; GASTROESOPHAGEAL REFLUX; HUMANS; HYDROGEN-ION CONCENTRATION; MALE; MIDDLE AGED; OMEPRAZOLE; STATISTICS AS TOPIC; YOUNG ADULT;

EID: 78751512644     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2010.04544.x     Document Type: Article

References (33)

1. Olbe L, Carlsson E, Lindberg P,. A proton-pump inhibitor expedition: the case histories of omeprazole and esomeprazole. Nat Rev Drug Discov 2003; 2: 132-9.
2. Sachs G, Shin JM, Howden CW,. Review article: the clinical pharmacology of proton pump inhibitors. Aliment Pharmacol Ther 2006; 23: 2-8.
3. Lind T, Rydberg L, Kylebäck A, et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861-7.
4. Röhss K, Hasselgren G, Hedenstrom H,. Effect of esomeprazole 40 mg vs. omeprazole 40 mg on 24-hour intragastric pH in patients with symptoms of gastroesophageal reflux disease. Dig Dis Sci 2002; 47: 954-8.
5. Miner P Jr, Katz PO, Chen Y, et al. Gastric acid control with esomeprazole, lansoprazole, omeprazole, pantoprazole, and rabeprazole: a five-way crossover study. Am J Gastroenterol 2003; 98: 2616-20.
6. Wilder-Smith CH, Röhss K, Nilsson-Pieschl C, et al. Esomeprazole 40 mg provides improved intragastric acid control as compared with lansoprazole 30mg and rabeprazole 20 mg in healthy volunteers. Digestion 2003; 68: 184-8.
7. Röhss K, Lind T, Wilder-Smith C,. Esomeprazole 40 mg provides more effective intragastric acid control than lansoprazole 30 mg, omeprazole 20 mg, pantoprazole 40 mg and rabeprazole 20 mg, in patients with gastroesophageal reflux symptoms. Eur J Clin Pharmacol 2004; 60: 531-9. (Pubitemid 39517904)
8. Miehlke S, Madisch A, Kirsch C, et al. Intragastric acidity during treatment with esomeprazole 40 mg twice daily or pantoprazole 40 mg twice daily-a randomized, two-way crossover study. Aliment Pharmacol Ther 2005; 21: 963-7.
9. Kahrilas PJ, Falk GW, Johnson DA, et al. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14: 1249-58.
10. Richter JE, Kahrilas PJ, Johanson J, et al. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656-65.
11. Castell DO, Kahrilas PJ, Richter JE, et al. Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol 2002; 97: 575-83.
12. Labenz J, Armstrong D, Lauritsen K, et al. A randomized comparative study of esomeprazole 40 mg versus pantoprazole 40 mg for healing erosive esophagitis: the EXPO study. Aliment Pharmacol Ther 2005; 21: 739-46.
13. Schmitt C, Lightdale CJ, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of standard doses of esomeprazole (40 mg) and omeprazole (20 mg) for the treatment of erosive esophagitis. Dig Dis Sci 2006; 51: 844-50. (Pubitemid 44030800)
14. Lauritsen K, Deviere J, Bigard MA, et al. Esomeprazole 20 mg and lansoprazole 15 mg in maintaining healed reflux oesophagitis: Metropole study results. Aliment Pharmacol Ther 2003; 17: 333-41. (Pubitemid 36259395)
15. Labenz J, Armstrong D, Lauritsen K, et al. Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive esophagitis: results from the EXPO study. Aliment Pharmacol Ther 2005; 22: 803-11.
16. Armstrong D, Talley NJ, Lauritsen K, et al. The role of acid suppression in patients with endoscopy-negative reflux disease: the effect of treatment with esomeprazole or omeprazole. Aliment Pharmacol Ther 2004; 20: 413-21.
17. Shimatani T, Kuroiwa T, Moriwaki M, et al. Acid-suppressive effects of generic omeprazole: comparison of three brands of generic omeprazole with original omeprazole. Dig Liver Dis 2006; 38: 554-9.
18. Karlsson A, Lövgren K, Rosén L, Tivert AM,. An investigation of the pharmaceutical quality of non-Astra authorised omeprazole products-a comparative study. Int Pharmacy J 1996; 10: 210-3.
19. Hassan-Alin M, Andersson T, Niazi M, et al. A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects. Eur J Clin Pharmacol 2005; 60: 779-84.
20. Andersson T, Röhss K, Bredberg E, et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole. Aliment Pharmacol Ther 2001; 15: 1563-9.
21. Furuta T, Ohashi K, Kosuge K, et al. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans. Clin Pharmacol Ther 1999; 65: 552-61.
22. Sagar M, Tybring G, Dahl ML, et al. Effects of omeprazole on intragastric pH and plasma gastrin are dependant on the CYP2C19 polymorphism. Gastroenterology 2000; 119: 670-6.
23. Shirai N, Furuta T, Moriyama Y, et al. Effects of CYP2C19 genotypic differences in the metabolism of omeprazole and rabeprazole on intragastric pH. Aliment Pharmacol Ther 2001; 15: 1929-37. (Pubitemid 34014349)
24. Kirsch C, Morgner A, Miehlke S,. Relevance of cytochrome P450 polymorphisms in the treatment of Helicobacter pylori infection and gastroesophageal reflux disease. Curr Pharmacogenomics 2006; 4: 1-10.
25. Tsai HH, Chapman R, Shepherd A, et al. Esomeprazole 20 mg on demand is more acceptable to patients than continuous lansoprazole 15 mg in the long-term maintenance of endoscopy-negative gastroesophageal reflux patients: the COMMAND Study. Aliment Pharmacol Ther 2004; 20: 657-65.
26. Morgner-Miehlke A, Petersen KU, Miehlke S, Labenz J,. Esomeprazole: potent acid suppression in the treatment of acid-related disorders. Exp Rev Clin Immunol 2005; 1: 511-27.
27. Morgner A, Miehlke S, Labenz J,. Esomeprazole: prevention and treatment of NSAID-induced symptoms and ulcers. Exp Opin Pharmacother 2007; 8: 975-88.
28. Lightdale CJ, Schmitt C, Hwang C, et al. A multicenter, randomized, double-blind, 8-week comparative trial of low-dose esomeprazole (20 mg) and standard-dose omeprazole (20 mg) in patients with erosive esophagitis. Dig Dis Sci 2006; 51: 852-7. (Pubitemid 44030802)
29. Burget DW, Chiverton SG, Hunt RH,. Is there an optimal degree of acid suppression for healing of duodenal ulcers? A model of the relationship between ulcer healing and acid suppression. Gastroenterology 1990; 99: 345-51.
30. Armstrong D,. Review article: gastric pH-the most relevant predictor of benefit in reflux disease? Aliment Pharmacol Ther 2004; 20: 19-26.
31. Schwab M, Klotz U, Hofmann U, et al. Esomeprazole-induced healing of gastroesophageal reflux disease is unrelated to the genotype of CYP2C19: evidence from clinical and pharmacokinetic data. Clin Pharmacol Ther 2005; 78: 627-34.
32. Xie HG, Stein CM, Kim RB, et al. Allelic, genotypic and phenotypic distributions of the S-mephenytoin 4′-hydroxylase (CYP2C19) in healthy Caucasian populations of European descent throughout the world. Pharmacogenetics 1999; 9: 539-49.
33. Bertilsson L,. Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 1995; 29: 192-209.